High-throughput isolation of SARS-CoV-2 nucleocapsid antibodies for improved antigen detection
Biochemical and Biophysical Research Communications · 2023
DOI: 10.1016/j.bbrc.2023.06.067 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biochemical and Biophysical Research Communications, 2023. Verfasst von Mizuki Fujisawa und 8 weiteren Autor:innen. Beteiligte Einrichtung: Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases, 1-23-1, Toyama, Shinjuku-ku, Tokyo, 162-8640, Japan; Dep…. Hauptthemen laut MEDLINE: SARS-CoV-2, COVID-19. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Japan Agency for Medical Research and Development.
Abstract (Originalsprache)
SARS-CoV-2 nucleocapsid protein (NP) is the main target for COVID-19-diagnostic PCR and antigen rapid diagnostic tests (Ag-RDTs). Ag-RDTs are more convenient than PCR tests for point-of-care testing or self-testing to identify the SARS-CoV-2 antigen. The sensitivity and specificity of this method depends mainly on the affinity and specificity of NP-binding antibodies; therefore, antigen-antibody binding is key elements for the Ag-RDTs. Here, we applied the high-throughput antibody isolation platform that has been utilized to isolate therapeutic antibodies against rare epitopes. Two NP antibodies were identified to recognize non-overlapping epitopes with high affinity. One antibody specifically binds to SARS-CoV-2 NP, and the other rapidly and tightly binds to SARS-CoV-2 NP with cross-reactivity to SARS-CoV NP. Furthermore, these antibodies were compatible with a sandwich enzyme-linked immunosorbent assay that exhibited enhanced sensitivity for NP detection compared to the previously isolated NP antibodies. Thus, the NP antibody pair is applicable to more sensitive and specific Ag-RDTs, highlighting the utility of a high-throughput antibody isolation platform for diagnostics development.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases, 1-23-1, Toyama, Shinjuku-ku, Tokyo, 162-8640, Japan; Department of Life Science and Medical Bioscience, Graduate School of Adv…
- Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases, 1-23-1, Toyama, Shinjuku-ku, Tokyo, 162-8640, Japan.
- Department of Pathology, National Institute of Infectious Diseases, 4-7-1, Gakuen, Musashi-murayama-shi, Tokyo, 208-0011, Japan.
- Department of Life Science and Medical Bioscience, Graduate School of Advanced Science and Engineering, Waseda University (TWIns), 2-2 Wakamatsu-cho, Shinjuku-ku, Tokyo, 162-8480, Japan; Research Institute for Science a…
- Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases, 1-23-1, Toyama, Shinjuku-ku, Tokyo, 162-8640, Japan. Electronic address: ytakahas@niid.go.jp.
Förderung
- Japan Agency for Medical Research and Development
Zitieren
APA
Fujisawa, M., Adachi, Y., Onodera, T., Shiwa-Sudo, N., Iwata-Yoshikawa, N., Nagata, N., Suzuki, T., Takeoka, S., & Takahashi, Y. (2023). High-throughput isolation of SARS-CoV-2 nucleocapsid antibodies for improved antigen detection. Biochemical and Biophysical Research Communications. https://doi.org/10.1016/j.bbrc.2023.06.067
Vancouver
Fujisawa M, Adachi Y, Onodera T, Shiwa-Sudo N, Iwata-Yoshikawa N, Nagata N, et al. High-throughput isolation of SARS-CoV-2 nucleocapsid antibodies for improved antigen detection. Biochemical and Biophysical Research Communications. 2023. doi:10.1016/j.bbrc.2023.06.067
BibTeX
@article{Fujisawa2023,
author = {Fujisawa, Mizuki and Adachi, Yu and Onodera, Taishi and Shiwa-Sudo, Nozomi and Iwata-Yoshikawa, Naoko and Nagata, Noriyo and Suzuki, Tadaki and Takeoka, Shinji and Takahashi, Yoshimasa},
title = {High-throughput isolation of SARS-CoV-2 nucleocapsid antibodies for improved antigen detection},
journal = {Biochemical and Biophysical Research Communications},
year = {2023},
doi = {10.1016/j.bbrc.2023.06.067}
}
EUVIMED